BACKGROUND & AIMS: The cytokine interleukin (IL)-10 is required to maintain immune homeostasis in the gastrointestinal tract. IL-10 null mice spontaneously develop colitis or are more susceptible to induction of colitis by infections, drugs, and autoimmune reactions. IL-13 regulates inflammatory conditions; its activity might be compromised by the IL-13 decoy receptor (IL-13Rα2). METHODS: We examined the roles of IL-13 and IL-13Rα2 in intestinal inflammation in mice. To study the function of IL-13Rα2, il10(-/-) mice were crossed with il13rα2(-/-) to generate il10(-/-)il13rα2(-/-) double knockout (dKO) mice. Colitis was induced with the gastrointestinal toxin piroxicam or Trichuris muris infection. RESULTS: Induction of colitis by interferon (IFN)-γ or IL-17 in IL-10 null mice requires IL-13Rα2. Following exposure of il10(-/-) mice to piroxicam or infection with T muris, production of IL-13Rα2 increased, resulting in decreased IL-13 bioactivity and increased inflammation in response to IFN-γ or IL-17A. In contrast to il10(-/-) mice, dKO mice were resistant to piroxicam-induced colitis; they also developed less severe colitis during chronic infection with T muris infection. In both models, resistance to IFN-γ and IL-17-mediated intestinal inflammation was associated with increased IL-13 activity. Susceptibility to colitis was restored when the dKO mice were injected with monoclonal antibodies against IL-13, confirming its protective role. CONCLUSIONS: Colitis and intestinal inflammation in IL10(-/-) mice results from IL-13Rα2-mediated attenuation of IL-13 activity. In the absence of IL-13Rα2, IL-13 suppresses proinflammatory Th1 and Th17 responses. Reagents that block the IL-13 decoy receptor IL-13Rα2 might be developed for inflammatory bowel disease associated with increased levels of IFN-γ and IL-17. Published by Elsevier Inc.
BACKGROUND & AIMS: The cytokine interleukin (IL)-10 is required to maintain immune homeostasis in the gastrointestinal tract. IL-10 null mice spontaneously develop colitis or are more susceptible to induction of colitis by infections, drugs, and autoimmune reactions. IL-13 regulates inflammatory conditions; its activity might be compromised by the IL-13 decoy receptor (IL-13Rα2). METHODS: We examined the roles of IL-13 and IL-13Rα2 in intestinal inflammation in mice. To study the function of IL-13Rα2, il10(-/-) mice were crossed with il13rα2(-/-) to generate il10(-/-)il13rα2(-/-) double knockout (dKO) mice. Colitis was induced with the gastrointestinal toxin piroxicam or Trichuris muris infection. RESULTS: Induction of colitis by interferon (IFN)-γ or IL-17 in IL-10 null mice requires IL-13Rα2. Following exposure of il10(-/-) mice to piroxicam or infection with T muris, production of IL-13Rα2 increased, resulting in decreased IL-13 bioactivity and increased inflammation in response to IFN-γ or IL-17A. In contrast to il10(-/-) mice, dKO mice were resistant to piroxicam-induced colitis; they also developed less severe colitis during chronic infection with T muris infection. In both models, resistance to IFN-γ and IL-17-mediated intestinal inflammation was associated with increased IL-13 activity. Susceptibility to colitis was restored when the dKO mice were injected with monoclonal antibodies against IL-13, confirming its protective role. CONCLUSIONS: Colitis and intestinal inflammation in IL10(-/-) mice results from IL-13Rα2-mediated attenuation of IL-13 activity. In the absence of IL-13Rα2, IL-13 suppresses proinflammatory Th1 and Th17 responses. Reagents that block the IL-13 decoy receptor IL-13Rα2 might be developed for inflammatory bowel disease associated with increased levels of IFN-γ and IL-17. Published by Elsevier Inc.
Authors: Motoko Morimoto; Masahiro Morimoto; Aiping Zhao; Kathleen B Madden; Harry Dawson; Fred D Finkelman; Margaret Mentink-Kane; Joseph F Urban; Thomas A Wynn; Terez Shea-Donohue Journal: J Immunol Date: 2006-01-01 Impact factor: 5.422
Authors: D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick Journal: J Clin Invest Date: 1996-08-15 Impact factor: 14.808
Authors: Thirumalai R Ramalingam; John T Pesce; Faruk Sheikh; Allen W Cheever; Margaret M Mentink-Kane; Mark S Wilson; Sean Stevens; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Joseph F Urban; Raymond P Donnelly; Thomas A Wynn Journal: Nat Immunol Date: 2007-12-09 Impact factor: 25.606
Authors: Sara L Hall; Theresa Baker; Stephane Lajoie; Phoebe K Richgels; Yanfen Yang; Jaclyn W McAlees; Adelaide van Lier; Marsha Wills-Karp; Umasundari Sivaprasad; Thomas H Acciani; Timothy D LeCras; Jocelyn Biagini Myers; Melinda Butsch Kovacic; Ian P Lewkowich Journal: J Allergy Clin Immunol Date: 2016-06-11 Impact factor: 10.793
Authors: Dawn C Newcomb; Madison G Boswell; Matthew M Huckabee; Kasia Goleniewska; Daniel E Dulek; Sara Reiss; Nicholas W Lukacs; Jay K Kolls; R Stokes Peebles Journal: J Immunol Date: 2011-12-30 Impact factor: 5.422
Authors: Melissa H Bloodworth; Dawn C Newcomb; Daniel E Dulek; Matthew T Stier; Jacqueline Y Cephus; Jian Zhang; Kasia Goleniewska; Jay K Kolls; R Stokes Peebles Journal: Infect Immun Date: 2016-04-22 Impact factor: 3.441
Authors: Stephen C Pflugfelder; Cintia S De Paiva; Quianta L Moore; Eugene A Volpe; De-Quan Li; Koray Gumus; Mahira L Zaheer; Rosa M Corrales Journal: Invest Ophthalmol Vis Sci Date: 2015-11 Impact factor: 4.799